<DOC>
	<DOCNO>NCT01616953</DOCNO>
	<brief_summary>The purpose research determine patient 's bone marrow tissue help regenerate bone area jaw implant place . The name process call Bone Repair Cell ( BRC ) Therapy . A sample bone marrow tissue collect sent laboratory process form cell . These new cell transplant regenerative site . The researcher test see cell ( BRC ) help form bone . The research also determine implant stable area new bone growth .</brief_summary>
	<brief_title>Cell Therapy Craniofacial Bone Defects</brief_title>
	<detailed_description>Up 20 ( twenty ) subject alveolar defect secondary cleft ( n=10 ) trauma ( n=10 ) , select participate study . Among 20 patient , total 60 defect site evaluate bone regeneration follow therapy , subject evaluate one four site . Once enrol , subject two group ( cleft trauma ) randomly assign receive one two possible treatment , traditional autogenous bone graft cell therapy ( ixmyelocel-T )</detailed_description>
	<mesh_term>Cleft Palate</mesh_term>
	<criteria>Age range : 18 60 yrs Gender : Male female Patients must able willing follow study procedure instruction . Patients must read , understood sign informed consent Missing tooth criterion : Patients miss least one maxillary lateral incisor secondary cleft lip and/or palate : compromise bone support installation dental implant ( ) ( &gt; 3 mm deficiency horizontal and/or vertical bone height ) adequate interdental arch space dental implant restoration bony continuity cleft segment adequate interproximal space ( adjacent teeth ) dental implant installation Patients miss multiple ( 14 teeth ) teeth secondary trauma : maxillary mandibular anterior segment ( second premolar second premolar ) compromise bone support installation dental implant ( ) ( &gt; 3 mm deficiency horizontal and/or vertical bone height ) adequate interdental arch space dental implant restoration Allergies hypersensitivity study related medication : dexamethasone , chlorhexidine , ibuprofen . For patient allergic amoxicillin comparable substitute antibiotic use . Hematologic disorders/ blood dyscrasia . Patients blood drawn complete blood count ( CBC ) test . Current University Michigan Health System normal lab value follow : white blood count ( WBC : 4.010.0 x103/cmm ) , red blood count ( RBC : male 4.505.90 x103/cmm ; female 3.905.30x103/cmm ) , hemoglobin ( HgB : male 1317.3gm/dl ; female 1216gm/dl ) , Hct ( male 3950.2 % ; female 3548 % ) , mean corpuscular volume ( MCV : 80100fl ) , mean corpuscular hemoglobin ( MCH : 2535 pg ) , mean corpuscular hemoglobin concentration ( MCHC : 3037 % ) , red cell distribution width ( RDW : 11.515.5 % ) , Plt ( 150450x103/cmm ) . Active infectious disease Liver kidney dysfunction/failure Patients blood drawn serum laboratory test , include creatinine , blood urea nitrogen , aspartate aminotransferase test ( AST ) , alanine aminotransferase test ( ALT ) , bilirubin . All must within normal limit patient include study . Current University Michigan Health System normal lab value follow : *Creatinine ( male 0.71.3 mg/dl female 0.51.0 mg/dl ) blood urea nitrogen ( BUN : 820 mg/dl ) AST ( 830 IU/L ) ALT ( 735 IU/L ) Bilirubin ( 0.21.2 mg/dl ) . Laboratory value define normal renal hepatic function , well criterion exclusion metabolic bone disease consistent establish University Michigan Health System ( UMHS ) . Normal clinical value use help assure health subject trial . Potential subject whose laboratory value fall outside UMHS normal range require medical clearance primary care provider prior participation . Endocrine disorders/dysfunctions ( i.e uncontrolled Type I II diabetes , glycosylated hemoglobin [ HA1C &gt; 7 % } ) Cancer The explicit definition cancer use exclude patient consistent described National Cancer Institute ( NCI ) , National Institutes Health . According NCI , cancer disease abnormal cell divide without control invade nearby tissue ( invasive disease ) . These include carcinoma , sarcoma , leukemia , lymphoma . Any patient history invasive disease exclude study . Patients currently use bisphosphonates history bisphosphonate use exclude trial . HIV+ Metabolic Bone Diseases Patients metabolic bone diseases Paget 's disease , hypercalcemia , moderate severe vitamin D3 abnormalities metabolic bone disease include osteoporosis osteoporotic fracture exclude . The following scale use determine osteoporosis patient bone mass density ( BMD determination : Normal = T score 1.0 standard deviation [ SD ] ) ; Osteopenia = T score 1.0 2.5 SD ; Osteoporosis = T score 2.5 SD . Pregnant woman Female patient childbearing potential exclude except use hormonal barrier method birth control ( oral parenteral contraceptive , diaphragm plus spermicide , condom ) . Pregnancy status determine urine test patient pregnant , determine positive test , exclude study Patients congenital metabolic bone disorder Subjects comorbid condition would affect study outcome interpretation study result exclude Subjects significant concomitant drug therapy systemic condition ( i.e . cardiovascular disease , renal dysfunction ) include study . Occasional short term use ( 714 day ) analgesic common cold medication permit . Such use medication review recorded Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>dental implant</keyword>
</DOC>